10QSB/A

                                   FORM 10-QSB

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

(X)  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934
                                        
For the Quarter Ended     July 31, 1996                                       
                         
( )   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

For the transition period from ____________  to  ____________                 
               

Commission File No.      0-11572                                               
                          
                              Endorex Corporation                             
            (Exact name of registrant as specified in its charter)  

         Delaware                                 41-1505029                   
(State of other jurisdiction of      (I.R.S. Employer Identification
 incorporation or organization)       Number)

          
      3233 15th Street South, Fargo, ND                    58104  
(Address of principal executive offices)               (Zip Code)

Issuer's telephone number, including area code     (701) 232-9575            
                                    
                         ImmunoTherapeutics, Inc.                              
(Former name, former address and former fiscal year, if changed since last
report)                                              

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15 (d) of the Securities Exchange Act during the past 12 months (or for
such shorter period that the registrant was required to file such reports), 
and (2) has been subject to such filing requirements for the past 90 days. 

                                  Yes  X  No   

At September 8 1996, 16,262,047 shares of the registrant's common stock 
 (par value, $.001 per share) were outstanding.



SIGNATURES


Pursuant to requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.                            

                                        IMMUNOTHERAPEUTICS, INC.



                                    __/s/__________________ 
                                    Gerald J. Vosika
                                    President and Director of the Company



                                    __/s/__________________  
                                    James W. Burrow
10/28/96                            Chief Financial Officer
           

EX-27

 

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS AMMENDED FINANCIAL INFORMATION EXTRACTED
FROM THE CONSOLIDATED BALANCE SHEET AND THE CONSOLIDATED
STATEMENTS
OF OPERATION.

       
                             
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          JAN-31-1996
<PERIOD-END>                               JUL-30-1996
<CASH>                                        1,829,018
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             1,882,840
<PP&E>                                          53,824
<DEPRECIATION>                                  91,950
<TOTAL-ASSETS>                               2,158,338
<CURRENT-LIABILITIES>                            9,524
<BONDS>                                              0
<COMMON>                                        18,042
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                   2,148,817
<TOTAL-LIABILITY-AND-EQUITY>                 2,158,338
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                         0
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0